2025-12-19 - Analysis Report
Okay, here's a comprehensive report on Eli Lilly (LLY) based on the data provided:

**0) Overview**

*   **Ticker:** LLY
*   **Company Name:** Eli Lilly and Co.
*   **Overview:** A pharmaceutical company developing and marketing a variety of human pharmaceutical products.

**1) Return Rate Comparison**

*   **LLY Cumulative Return:** 300.11%
*   **VOO (S&P 500) Cumulative Return:** 99.09%
*   **Divergence:**
    *   Current: 199.3
    *   Relative Divergence: 82.6

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO). The cumulative return is substantially higher, and the divergence indicates a strong positive difference in performance. The relative divergence of 82.6 suggests that the current divergence is high compared to its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta | Cap(B) |
|------------|--------|-------|--------|------|--------|
| 2015-2017  | 11.0%  | 76.1% | -17.0% | -0.0 | 75.7   |
| 2016-2018  | 39.0%  | 68.9% | 24.0%  | -0.0 | 103.7  |
| 2017-2019  | 41.0%  | 68.9% | 19.0%  | 0.4  | 117.8  |
| 2018-2020  | 34.0%  | 79.8% | 10.0%  | 0.4  | 151.4  |
| 2019-2021  | 53.0%  | 79.8% | 7.0%   | 0.5  | 247.6  |
| 2020-2022  | 64.0%  | 79.8% | 65.0%  | 0.4  | 328.0  |
| 2021-2023  | 125.0% | 78.9% | 124.0% | 0.2  | 522.6  |
| 2022-2024  | 134.0% | 81.2% | 113.0% | 0.2  | 692.1  |
| 2023-2025  | 191.0% | 83.5% | 128.0% | 0.2  | 947.5  |

*   **CAGR:** Compounded Annual Growth Rate increased from 11% (2015-2017) to 191% (2023-2025) showing substantial growth.
*   **MDD:** Maximum Drawdown is high but relatively stable, ranging from 68.9% to 83.5%.
*   **Alpha:** Positive and significantly increasing, especially in recent years. This indicates that LLY is generating excess returns compared to what would be expected based on its beta.
*   **Beta:** Low and relatively stable, around 0.2 to 0.5. This suggests that LLY's price is not very sensitive to market movements.
*   **Cap:** Company capitalization is increasing.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 1056.88
*   **Previous Close:** 1041.79
*   **Change:** 1.45%
*   **5-day SMA:** 1048.53
*   **20-day SMA:** 1041.15
*   **60-day SMA:** 925.23

**Analysis:** The current price is above both the 5-day and 20-day SMAs, indicating a short-term upward trend. All of the SMAs is less than the current price which means the stock has been trending upwards. The recent change of 1.45% shows a positive upward direction.

**3) Indicator Analysis**

*   **MRI:** 0.7 (Medium Investment Recommended)
*   **RSI:** 45.68 (Neutral)
*   **PPO:** -0.41 (Slightly Bearish)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash
*   **Recent Divergence Change:** 10.1% (Positive, indicating short-term increase)
*   **Expected Return:** 51.6% (High expected return compared to S&P 500 over 2 years)

**Analysis:** The MRI suggests a medium investment recommendation. The RSI is neutral, indicating neither overbought nor oversold conditions. The PPO is slightly negative, suggesting a slightly bearish trend. The Hybrid Signal suggests to buy 100% of cash. The recent positive divergence change confirms the upward trend, and the expected return is very high.

**4) Recent News & Significant Events**

*   **Retatrutide Breakthrough/Orforglipron FDA Timeline:** Positive news related to potential new drugs and regulatory progress.
*   **LLY outperforming Nvidia:** Highlights strong recent performance compared to a major tech stock.
*   **Bank of America on Weight-Loss Drug Dominance:** Suggests the market may be undervaluing LLY's potential in the weight-loss drug market.
*   **Where Will Eli Lilly Be in 10 Years?**: Discussions about the long-term prospects of the company.
*   **Healthcare Giants Raise Dividends:** Positive for investors seeking income.
*   **Why Is Novo Nordisk Stock Falling?:** Could indirectly benefit LLY if it leads to a shift in investor sentiment towards LLY's weight-loss drugs.

**Analysis:** The news is overwhelmingly positive, focusing on potential blockbuster drugs, strong market performance, and analyst optimism. The articles highlight the potential of LLY in the weight-loss drug market.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.70)
*   **Target Price (avg/high/low):** 1093.22 / 1500.00 / 770.00

**Analysis:** Analyst consensus is strongly positive, with a "Buy" recommendation. The average target price suggests a potential upside from the current price.

**5) Recent Earnings Analysis:**

| Date       | EPS  | Revenue     |
|------------|------|-------------|
| 2025-10-30 | 6.22 | 17.60 B$    |
| 2025-08-07 | 6.30 | 15.56 B$    |
| 2025-05-01 | 3.07 | 12.73 B$    |
| 2024-10-30 | 1.08 | 11.44 B$    |
| 2025-10-30 | 1.08 | 11.44 B$    |

**Analysis:** EPS and Revenue have been generally increasing over the past few quarters.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $17.60B    | 82.91%       |
| 2025-06-30   | $15.56B    | 84.27%       |
| 2025-03-31   | $12.73B    | 82.53%       |
| 2024-12-31   | $13.53B    | 82.24%       |
| 2024-09-30   | $11.44B    | 81.02%       |

**Capital and Profitability:**

| Quarter      | Equity     | ROE      |
|--------------|------------|----------|
| 2025-09-30   | $23.79B    | 23.46%   |
| 2025-06-30   | $18.27B    | 30.98%   |
| 2025-03-31   | $15.76B    | 17.50%   |
| 2024-12-31   | $14.19B    | 31.07%   |
| 2024-09-30   | $14.24B    | 6.81%    |

**Analysis:** Revenue is trending upward. Profit margins are very high and stable. Equity has generally increased. ROE has fluctuated, but the overall trend is upwards.

**7) Comprehensive Analysis**

Eli Lilly (LLY) is exhibiting strong financial performance and positive market sentiment. Key takeaways:

*   **Outperformance:** LLY has significantly outperformed the S&P 500 (VOO).
*   **Growth:** Revenue, EPS, and CAGR are increasing.
*   **Profitability:** High and stable profit margins.
*   **Market Sentiment:** Positive news flow, analyst "Buy" consensus, and a medium MRI.
*   **Technicals:** Positive divergence change and current price above key SMAs.
*   **Weight-Loss Drug Market:** A major driver of future potential.
*   **Risk:** High MDD

**Overall, the data suggests a positive outlook for Eli Lilly. While the high MDD indicates a need to be mindful of potential volatility, the strong financial performance, positive market sentiment, and promising drug pipeline make it an attractive investment opportunity.**


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.